We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




World's First Reusable Biochip Architecture Designed

By LabMedica International staff writers
Posted on 07 Jul 2010
The world's first reusable biochip architecture has been developed for the commercial market. More...
These reusable integrated fluidic circuits (IFCs) will dramatically lower single nucleotide phenotype (SNP) genotyping costs and are designed to support accelerated sample throughput, while maintaining data quality of 99.75% or greater accuracy and 99% or greater call rates.

Fluidigm Corp. (South San Francisco, CA, USA) initially invented this architecture to support a progressive new program driven by the Agricultural Research Service (ARS; Washington, DC, USA), the chief scientific research agency of the United States Department of Agriculture (USDA). The program's goal is to drive high sample throughput genotyping down to a penny-per-data-point, which would enable widespread adoption of genetic analysis in vegetable and fruit seeds, livestock (such as cattle, pigs, sheep, poultry), and fishery management. This will significantly improve the quality and quantity of the food supply, while lowering production costs.

Fluidigm's new reuse architecture represents the first step towards making this goal a reality. "We are elated that Fluidigm's reusable biochip can contribute to improving the food supply and bring the benefits of genetic analysis and testing to AgBio scientists and producers around the globe,” said Gajus Worthington, president and chief executive officer of Fluidigm. "A year ago, when we set out to develop a reusable chip, the notion was controversial. But we thought the idea was compelling--and so did our customers. I am so pleased that our scientists and engineers weren't inhibited by traditional thinking that believed reusability in the microfluidic device was impossible. Instead of acquiescing to the norm, they overcame the dogma of the past and achieved an engineering marvel. I believe reusability will be revolutionary for our industry and the life science fields we serve. Reusability lowers costs, eliminates waste, and confers flexibility. I can't think of an invention we've made at Fluidigm that has excited me more.”

Mr. Worthington noted that the company had also recently introduced an ultra-fast thermal cycler--the FC1 Cycler--and is adding a new IFC controller designed to support reusable chips. Initially the reuse family of products will include chips, a new controller, the FC1 Cycler, and either the EP1 Reader or the BioMark system. A new chip and instrument will be announced soon to start high-sample throughput genotyping customers down the reusable path. "We expect to bring additional chip configurations, instruments, and assays to the market place over this year and next that will make reusability practical for more customers, continue to lower costs per data point and set a course for genetic analysis to contribute to a better food supply for the world,” stated Mr. Worthington.

Application of Fluidigm's reuse technology will also contribute to the life-science industry's competitiveness. "We have recently added the Fluidigm system to the family of genomic services we offer our clients. We are seeing a great and growing need for high quality, cost-effective genetic testing services from plant and animal researchers. We have done some work in this area, but cost has always been a barrier. Fluidigm's new reusable chips will enable our agriculture-based customers to realize the tremendous benefits of SNP genotyping at significantly reduced costs,” said Steve McPhail, Expression Analysis's president and chief executive officer. Expression Analysis, Inc. (Durham, NC,USA) is a leading provider of genomic services for clinical trials and research.

Fluidigm develops, manufactures, and markets proprietary IFC systems that significantly improve productivity in life science research. Fluidigm's IFCs enable the simultaneous performance of thousands of sophisticated biochemical measurements in extremely minute volumes.

Related Links:

Fluidigm



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Blood Glucose Test Strip
AutoSense Test
New
Silver Member
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Platelets sequester cfDNA during circulation (Murphy L. et al., Science, 2025; DOI: 10.1126/science.adp3971)

Platelets Could Improve Early and Minimally Invasive Detection of Cancer

Platelets are widely recognized for their role in blood clotting and scab formation, but they also play a crucial role in immune defense by detecting pathogens and recruiting immune cells.... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Pathology

view channel
image: Researchers Marco Gustav (right) and MD Nic G. Reitsam (left) discuss the study data (Photo courtesy of Anja Stübner/EKFZ)

AI Model Simultaneously Detects Multiple Genetic Colorectal Cancer Markers in Tissue Samples

Colorectal cancer is a complex disease influenced by multiple genetic alterations. Traditionally, studies and diagnostic tools have focused on predicting only one mutation at a time, overlooking the interplay... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.